Carol Ann Werther has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.
Ms. Werther joins HCW with over 20 years of experience in the biotechnology sector both as a research analyst and portfolio manager, including stints with CRT Capital Group, Summer Street Research Partners, Think Equity Partners, Adams, Harkness & Hill and Cowen.
“We are excited to have Carol join HCW’s biotech research team as our seventh senior analyst,” CEO, Mark Viklund, said in a statement. “Her depth of knowledge in the biotechnology sector acquired over her distinguished career will enable HCW to provide differentiated investment advice to our clients.”
